SCYNEXIS, Inc. (NASDAQ:SCYX) Files An 8-K Submission of Matters to a Vote of Security Holders

SCYNEXIS, Inc. (NASDAQ:SCYX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 15, 2017, SCYNEXIS, Inc. (the “Company) held its 2017
Annual Meeting of Stockholders (the Annual Meeting). Set forth
below is a brief description of each matter considered and voted
upon at the Annual Meeting, together with the final tally of the
number of votes cast for, against or withheld, as well as the
number of abstentions and broker non-votes as to each such matter,
including a separate tabulation with respect to each of the seven
directors. A more complete description of each matter is set forth
in the Company’s definitive proxy statement for the Annual Meeting
filed with the Securities and Exchange Commission on April 26, 2017
(the Proxy Statement).
Proposal 1: Election of Directors.
The Company’s stockholders elected each of the seven nominees
proposed by the Company for election as directors, to serve until
the 2018 annual meeting of stockholders, and until their successors
are elected and have qualified, or until their earlier death,
resignation or removal. The tabulation of votes on this matter was
as follows:
Director Nominee
Shares Voted For
Shares Withheld
Steven C. Gilman, Ph.D.
Ann F. Hanham, Ph.D.
David Hastings
Guy Macdonald
Patrick Machado
Marion McCourt
Marco Taglietti, M.D.
There were 7,424,888>broker non-votes for this proposal.
Proposal 2: Ratification of Selection of Independent Registered
Public Accounting Firm
The Company’s stockholders ratified the appointment of Deloitte
Touche LLP as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2017. The
tabulation of votes on this matter was as follows:
Shares voted for:
Shares voted against:
Shares abstaining:
Broker non-votes:


SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

An ad to help with our costs